Rani Therapeutics director granted 123,600 stock options

Rani Therapeutics Holdings, Inc. director and ten percent owner Imran Mir A received a grant of options to acquire 123,600 shares of Class A Common Stock.

Rhea-AI Filing Summary

Rani Therapeutics Holdings, Inc. director and ten percent owner Imran Mir A received a grant of options to acquire 123,600 shares of Class A Common Stock. The options have an exercise price of 0.9515 per share and expire on May 27, 2036.

These director stock options vest in full on the first anniversary of the grant date, subject to continuous service, or earlier upon the company’s next annual stockholder meeting or a Change in Control, also subject to continuous service. Following this grant, the filing shows 123,600 derivative securities held directly.

Insider Trade Summary

Grant/Award: 123,600 shares

Grant/Award 1 txn

Insider IMRAN MIR A

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	123,600	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 123,600 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Plan), each subject to the Reporting Person's Continuous Service through such date.

Key Figures

Option grant size: 123,600 options Exercise price: 0.9515 per share Expiration date: May 27, 2036 +1 more

4 metrics

Option grant size 123,600 options Director stock option covering Class A Common Stock

Exercise price 0.9515 per share Exercise price for the director stock option

Expiration date May 27, 2036 Option expiration for director stock option grant

Post-grant derivative holdings 123,600 derivative securities Total derivative securities following the transaction

Key Terms

Director Stock Option (Right to Buy), 2021 Equity Incentive Plan, Change in Control, Continuous Service

4 terms

Director Stock Option (Right to Buy) financial

"security_title: "Director Stock Option (Right to Buy)""

2021 Equity Incentive Plan financial

"defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")"

Change in Control financial

"upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Continuous Service financial

"subject to the Reporting Person's Continuous Service through such vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Imran Mir A report in this Rani Therapeutics (RANI) Form 4?

Imran Mir A reported receiving a stock option grant for 123,600 shares. These options allow him to buy Rani Therapeutics Class A Common Stock at an exercise price of 0.9515 per share, reflecting a compensation-related award rather than an open-market purchase or sale.

How many Rani Therapeutics (RANI) shares are covered by the new stock options?

The new director stock option grant covers 123,600 underlying shares. Each option is exercisable into one share of Class A Common Stock, so the award represents potential future ownership of 123,600 shares if the options vest and are exercised.

What is the exercise price and expiration date of the RANI options granted?

The options have an exercise price of 0.9515 per share and expire on May 27, 2036. This means Imran Mir A can, once vested, buy shares at 0.9515 any time before the May 27, 2036 expiration date, subject to plan terms.

When do Imran Mir A’s Rani Therapeutics (RANI) options vest?

The options vest in full on the first anniversary of the grant date. Vesting also can occur earlier if Rani Therapeutics holds its next annual stockholder meeting or experiences a Change in Control, provided Imran Mir A maintains continuous service through the relevant date.

Is this Rani Therapeutics (RANI) Form 4 a market buy or sell of shares?

No, this Form 4 reflects a grant of stock options, not a market trade. The transaction is coded as a grant, award, or other acquisition, indicating compensation rather than an open-market purchase or sale of Rani Therapeutics stock.

How many Rani Therapeutics (RANI) derivative securities does Imran Mir A hold after this grant?

After the grant, the filing shows 123,600 derivative securities held directly. These represent the stock options granted in this transaction, each tied to one share of Class A Common Stock, contingent on vesting and future exercise decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 04:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

IMRAN MIR A

(Last) (First) (Middle)

C/O RANI THERAPEUTICS LLC

2051 RINGWOOD AVE

(Street)

SAN JOSE CALIFORNIA 95131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rani Therapeutics Holdings, Inc. [ RANI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$0.9515	05/28/2026		A		123,600		(1)	05/27/2036	Class A Common Stock	123,600	$0	123,600	D

Explanation of Responses:

1. The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the Reporting Person's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan (the "2021 Plan")) through such vesting date; provided that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Plan), each subject to the Reporting Person's Continuous Service through such date.

	/s/ Svai Sanford, Attorney-in-Fact	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)